|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
PSMAFore, SPLASH and ECLIPSE: Are They Different? "Presentation"
|
|
Thomas Hope, MD; Michael Morris, MD; and A. Oliver Sartor, MD
|
| At the 2024 UCSF-UCLA PSMA Conference, Thomas Hope, Michael Morris, and Oliver Sartor discuss the nuances of three trials—PSMAfore, SPLASH, and ECLIPSE—in the pre-chemotherapy metastatic CRPC setting, focusing on the ambition to advance Lutetium PSMA therapy earlier in treatment.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance |
| Ravi Madan, MD |
| Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. |
|
|
|
|
|
|
|
|
|
|
|
| Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations |
| Louise Emmett, MD, MBChB, FRACP, FAANMS |
| Alicia Morgans speaks with Louise Emmett about the use of radiopharmaceuticals in prostate cancer, particularly for frail patients. Professor Emmett focuses on dosing radioligand therapy in special situations and managing toxicity, particularly marrow and kidney toxicity. She highlights the need for individualized dosing strategies, noting that current protocols might not adequately treat high-volume disease. |
|
|
|
|
|
|
|
|
|
|
|
| Radioligand Therapy for Metastatic Castrate-Resistant Prostate Cancer: Radium-223, 177Lu-PSMA-617, New Agents, and Novel Combinations |
| Rashid K. Sayyid, MD, MSc, and Zachary Klaassen, MD, MSc |
| Radioligand therapy represents a promising treatment approach for mCRPC, focusing on targeted radiation delivery to cancer cells. Two FDA-approved agents, Radium-223 and 177Lu-PSMA-617, have shown efficacy in improving survival and quality of life, with Radium-223 specifically targeting bone metastases and 177Lu-PSMA-617 targeting PSMA-positive lesions. Ongoing research is exploring new radioligands and combination therapies to further enhance treatment outcomes in mCRPC patients. |
|
|
|
|
|
| Treatment Landscape in mCRPC |
| Matthew Rettig, MD |
| Matthew Rettig discusses the evolving treatment landscape for mCRPC, highlighting various FDA-approved therapies, including androgen receptor blockers, cytotoxic agents, immunotherapies, and radioligand treatments like 177Lu-PSMA-617. He emphasized the importance of precision oncology in improving outcomes, which involves metastatic biopsy, plasma analysis, circulating tumor cell analysis, and imaging for biomarker-directed treatments. |
|
|
|
|
|
|
|
|
|
|
| PSICHE Trial: PSMA Guided Approach for Biochemical Relapse After Prostatectomy- A Prospective Trial
|
| Giulio Francolini, MD
|
| Giulio Francolini presented findings from the PSICHE trial, a prospective study assessing a PSMA-guided treatment approach for biochemical relapse after radical prostatectomy. The trial included 174 patients who underwent 68Ga-PSMA PET/CT imaging to guide subsequent treatment: salvage radiotherapy for prostate fossa-limited disease, SBRT for pelvic nodal or oligometastatic disease, and androgen deprivation therapy for polymetastatic cases.
|
|
|
|
|
|
| PSMA Radioligand Therapy: The VISION and TheraP Trials |
| Michael Morris, MD |
| The VISION and TheraP trials demonstrated that ^177Lu-PSMA-617 significantly improves outcomes in men with PSMA-positive metastatic castration-resistant prostate cancer. The VISION trial showed extended overall survival and progression-free survival compared to standard care alone, while the TheraP trial found ^177Lu-PSMA-617 to be a viable alternative to cabazitaxel after docetaxel failure. These findings highlight the therapeutic potential of PSMA radioligand therapy in advanced prostate cancer. |
|
|
|
|
|
| Dosing of Radioligand Therapy in Special Situations And/or Toxicity |
| Louise Emmett, BSc(HONS), MBChB, FRACP, FAANMS, MD |
| Louise Emmett discusses radioligand therapy dosing considerations and toxicity in prostate cancer patients, emphasizing criteria for dose reductions and potential adverse effects. She highlights the commonality of marrow toxicity with PSMA-targeted radionuclide therapy and stressed the importance of monitoring disease progression to distinguish between treatment-related toxicity and underlying disease effects. |
|
|
|
|
|
| mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
|
| Jeremie Calais, MD, MSc
|
| Jeremie Calais presented notable advancements in radioligand therapy for PSMA-sensitive metastatic castrate-resistant prostate cancer at the 2024 American Urological Association (AUA) Annual Meeting. His talk provided insights into the current landscape and potential future directions for PSMA-targeted therapies.
|
|
|
|
|
|
|
|
|
|
|
